Details for New Drug Application (NDA): 020511

✉ Email this page to a colleague

NDA 020511 describes APHTHASOL, which is a drug marketed by Uluru and is included in one NDA. Additional details are available on the APHTHASOL profile page.

The generic ingredient in APHTHASOL is amlexanox. Additional details are available on the amlexanox profile page.

Summary for 020511

Tradename:	APHTHASOL
Applicant:	Uluru
Ingredient:	amlexanox
Patents:	0

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	PASTE;DENTAL			Strength	5%
Approval Date:	Dec 17, 1996	TE:		RLD:	No

Expired US Patents for NDA 020511

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Uluru	APHTHASOL	amlexanox	PASTE;DENTAL	020511-001	Dec 17, 1996	⤷ Subscribe	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.